Headquarters: Los Angeles, California, United States
Investors Number: 18.0
Technology: Rare Genetic Disorders
Last Funding Type: Series B
Funding Status: Early Stage Venture
Total Funding: 63200000.0
Last Funding Date: 2022-11-28
Founded Date: 2016-01-01
Industry: Early Drug Development